September 2026

-, 2026, All September 14th, 2026 Comments Off on Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in the lung, in line with prior results observed in healthy participants Robust target engagement of ALK5 observed with AGMB-447 in IPF patients Clinical Trial Application (CTA)

Read more

2026, All September 11th, 2026 Comments Off on Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Antwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company’s Special and Extraordinary General Shareholders’ Meeting held on September 11, 2026. The approved resolutions included the appointments of Marino

Read more

2026, All September 3rd, 2026 Comments Off on Agomab to Participate in Upcoming Investor Conferences

Agomab to Participate in Upcoming Investor Conferences

Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences: Citi’s 2026 Biopharma Back to School Conference. Thursday, September 10, 2026 in New York, NY. 2026 Cantor Global Healthcare Conference.

Read more